Author

F. Shala

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

B. Ahmetaj-Shala· 2 shared J. A. Mitchell· 2 shared N. S. Kirkby· 2 shared B. Liu· 1 shared C. Hao· 1 shared G. de Nucci· 1 shared H. Abou Saleh· 1 shared H. Herschman· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

B. Ahmetaj-Shala

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Tissue fibroblasts are a critical source of prostacyclin and anti-thrombotic

J. A. Mitchell, M. Vinokurova, M. E. Lopes-Pires, F. Shala, P. C. Armstrong, B. Ahmetaj-Shala, Y. Elghazouli, B. Liu, Y. Zhou, C. Hao, H. Herschman, N. S. Kirkby

The paper shows lung and other tissues produce prostacyclin via fibroblasts, providing systemic anti-thrombotic protection, challenging the traditional view that endothelium is the main source.

bioRxiv · Jan 11, 2022 · PreprintPharmacology & Toxicology

Metal-organic framework (MOF) nanomedicine preparations of sildenafil designed for the future treatment of pulmonary arterial hypertension

N. A. Mohamed, H. Abou Saleh, Y. Kameno, I. Marei, G. de Nucci, B. Ahmetaj-Shala, F. Shala, N. S. Kirkby, L. Jennings, R. P. Davies, P. D. Lickiss, J. A. Mitchell

This paper develops a nanomedicine formulation of sildenafil using MIL-89 MOF for controlled release in PAH treatment, showing delayed vasodilation.

bioRxiv · Jul 30, 2019 · PreprintPharmacology & Toxicology